{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=10&state=Minnesota", "query": { "state": "Minnesota", "city": "Rochester", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 2415, "total_pages": 242, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=11&state=Minnesota&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Rochester&page=9&state=Minnesota&page_size=10" }, "source": "local", "last_synced_at": "2026-10-28T15:24:32.085Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07441681", "title": "Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Advanced Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 454, "start_date": "2026-07-31", "completion_date": "2040-11-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T23:11:28.748Z", "location_count": 150, "location_summary": "Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 116 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07441681" }, { "nct_id": "NCT07415031", "title": "A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2026-05-06", "completion_date": "2028-02-16", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T17:14:27.675Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bellflower", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07415031" }, { "nct_id": "NCT07213791", "title": "A Study of LY4337713 in Participants With FAP-Positive Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Neoplasms", "Cholangiocarcinoma", "Colorectal Neoplasms", "Esophageal Neoplasms", "Ovarian Neoplasms", "Pancreatic Intraductal Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "LY4337713", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2025-10-22", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T23:11:06.778Z", "location_count": 20, "location_summary": "Newport Beach, California • Stanford, California • Miami, Florida + 14 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213791" }, { "nct_id": "NCT07159763", "title": "A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "MK-1406", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 10000, "start_date": "2025-09-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T18:54:11.981Z", "location_count": 123, "location_summary": "Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 107 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159763" }, { "nct_id": "NCT07054515", "title": "A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GM1 Gangliosidosis", "GM2 Gangliosidosis", "Niemann-Pick Type C Disease" ], "interventions": [ { "name": "AZ-3102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Azafaros B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 147, "start_date": "2025-06-30", "completion_date": "2028-06-14", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T02:31:47.579Z", "location_count": 5, "location_summary": "Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07054515" }, { "nct_id": "NCT07012395", "title": "A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis", "Colitis, Ulcerative", "Inflammatory Bowel Diseases", "Ulcerative Colitis" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "SPY001", "type": "DRUG" }, { "name": "SPY002", "type": "DRUG" }, { "name": "SPY003", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Spyre Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 645, "start_date": "2025-05-27", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T15:24:32.085Z", "location_count": 27, "location_summary": "Canoga Park, California • La Jolla, California • Lancaster, California + 24 more", "locations": [ { "city": "Canoga Park", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07012395" }, { "nct_id": "NCT06975787", "title": "Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis (LN)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" }, { "name": "Vonsetamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 90, "start_date": "2025-12-22", "completion_date": "2029-09-10", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T16:31:58.813Z", "location_count": 4, "location_summary": "San Francisco, California • Gainesville, Florida • Rochester, Minnesota + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06975787" }, { "nct_id": "NCT06772623", "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Carcinoma", "c-MET" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-03-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T16:47:11.262Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06772623" }, { "nct_id": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2025-05-16", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T14:15:50.036Z", "location_count": 136, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672146" }, { "nct_id": "NCT06655246", "title": "A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Cancer", "Gastrointestinal Stromal Cell Tumors", "Gastrointestinal Stromal Neoplasm", "Gastrointestinal Stromal Tumor (GIST)", "Gastrointestinal Stromal Tumor, Malignant" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "ziftomenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2025-03-27", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-27T15:32:03.713Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06655246" } ] }